Abacus LifeNASDAQ: ABL

ORLANDO, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock, including 10,000,000 shares of common stock being offered by the Company and 2,500,000 shares of common stock being offered by certain stockholders of the Company (the “Selling Stockholders”), at a price to the public of $8.00 per share. In connection with the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock from the Company and up to an additional 375,000 shares of common stock from the Selling Stockholders at the public offering price. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $100 million, excluding any exercise of the underwriters' option to purchase additional shares.

ORLANDO, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in leveraging longevity and actuarial technology to offer uncorrelated investment opportunities, today announced the commencement of an underwritten public offering of 12,500,000 shares of its common stock, including 10,000,000 shares of common stock to be sold by the Company and 2,500,000 to be sold by certain stockholders of the Company (the “Selling Stockholders”). The Company and the Selling Stockholders also expect to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock from the Company and up to an additional 375,000 shares of common stock from the Selling Stockholders.

Abacus Life, Inc. (NASDAQ:ABL ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Robert Phillips – Senior Vice President- Investor Relations and Corporate Affairs Jay Jackson – Chairman and Chief Executive Officer Bill McCauley – Chief Financial Officer Conference Call Participants Crispin Love – Piper Sandler Andrew Kligerman – TD Cowen Mike Grondahl – Northland Securities Operator Good day, ladies and gentlemen, and thank you for standing by. At this time all participants are in a listen-only mode.

- Delivered Continued Revenue and Profitability Growth While Executing on Strategic Initiatives - - Third Quarter 2024 Total Revenue Grows 33% Year-over-Year to $28.1 Million - - Due to Non-Cash Increase in Warrant Liability of $8.7M; GAAP Net Loss of $5.1M - - Adjusted Net Income Grows 65% Year-over-Year to $14.9 Million - - Adjusted EBITDA Grows 54% Year-over-Year to $16.7 Million - ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering global alternative asset manager specializing in leveraging longevity data and actuarial technology to offer uncorrelated investment opportunities, today reported results for the third quarter ended September 30, 2024.

Abacus Life, Inc. (ABL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #SMBs--Cambridge Savings Bank has provided a new credit facility to Fabrizia Spirits, a leading citrus spirits manufacturer in the United States.

ORLANDO, Fla., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading global alternative asset manager focused on lifespan-based financial products, today announced it will release its Third Quarter 2024 financial results after the market closes on Thursday, November 7, 2024.

Does Abacus Life, Inc. (ABL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Abacus Life, Inc. (ABL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.